Dr Laeeq Malik is a cancer physician with subspecialty interest in the treatment of breast cancer and genitourinary malignancies. He also has a particular interest in conducting early phase clinical trials. He has obtained specific training in the USA and gained significant experience in conducting various types of phase I and II oncology studies such as first-in-human, multi-arm Phase Ib, organ dysfunction (liver and renal), bioequivalence, food effect, drug-drug interaction, QTc interval studies, and studies with extensive pharmacology and pharmacogenomics guided designs. He has been a Principal investigator/Co-Principal investigator & sub-investigator on several phase I and II studies locally and overseas. During his research training, he played an important collaborative role in the development of several novel agents. More recently, he has contributed significantly to the initiation of early phase clinical studies at The Canberra Hospital. He is currently Co-Principal investigator on phase I studies of new cancer agents in patients with refractory and relapsed solid tumours in collaboration with investigators from University of Canberra and The Australian National University. He has been involved in the publication of several journal articles and invited book chapters.